|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||24.50 - 27.34|
|52 Week Range||16.70 - 53.69|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.
PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.
PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.